# The treatment of medial compartmental knee osteoarthritis (OA) symptoms with the KineSpring™ Unicompartmental Knee Arthroplasty (UKA) System

Submission date 26/06/2009	<b>Recruitment status</b> No longer recruiting	[X] Prospectively registered [] Protocol
<b>Registration date</b> 14/07/2009	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 12/09/2016	<b>Condition category</b> Musculoskeletal Diseases	<ul> <li>Individual participant data</li> <li>Record updated in last year</li> </ul>

### Plain English summary of protocol

Not provided at time of registration

### **Contact information**

**Type(s)** Scientific

**Contact name** Prof James B. Richardson

#### **Contact details**

Institute of Orthopaedics Robert Jones and Agnes Hunt Orthopaedic and District Hospital Oswestry Outcome Centre Oswestry, Shropshire United Kingdom SY10 7AG

**Type(s)** Scientific

**Contact name** Prof Jan Victor

**Contact details** Department of Orthopaedic Surgery and Traumatology University Hospital University of Gent De Pintelaan 185, 1P5 Gent Belgium 9000

#### Type(s)

Scientific

#### Contact name

Mr Rhys Williams

#### **Contact details**

University Hospital of Wales Cardiff and Vale NHS Trust Heath Park Cardiff United Kingdom CF14 4XW

#### Type(s)

Scientific

**Contact name** Mr Timothy Wilton

#### **Contact details**

Derbyshire Royal Infirmary Derby Hospitals Foundation London Road Derby United Kingdom DEL 2QY

#### Type(s)

Scientific

**Contact name** Mr Nicolas John London

#### **Contact details**

Harrogate District Hospital Harrogate & District NHS Foundation Trust Lancaster Park Road Harrogate United Kingdom HG2 7SX

### Type(s)

Scientific

**Contact name** Mr Nicolas John London

#### **Contact details**

The Duchy BMI Queens Road Harrogate United Kingdom HG2 0HF

### Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers KINE-0902

### Study information

#### Scientific Title

A multicentre open-label interventional study of patients with medial compartmental knee osteoarthritis (OA) symptoms treated with the KineSpring™ Unicompartmental Knee Arthroplasty (UKA) System

#### Acronym

COAST

#### **Study objectives**

The null hypothesis (H0) is that the Knee Society Score (KSS) for function derived from subjects treated with the KineSpring™ UKA System is inferior to a mean KSS for function of 80 which is widely reported in applicable literature: H0: KSS less than or equal to 80 - d

The alternative hypothesis (H1) is that the KSS for function associated with KineSpring™ UKA System subjects is not inferior: H1: KSS greater than 80 - d

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

- 1. University of Ghent, Belgium, 07/10/2009
- 2. Leeds West Research Ethics Committee, UK, 21/10/2009
- 3. All other centers have received ethics approval before recruitment of the first participant

### Study design

Prospective multicentre open-label non-randomised non-inferiority study

**Primary study design** Interventional

**Secondary study design** Non randomised study

**Study setting(s)** Hospital

**Study type(s)** Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Osteoarthritis of the knee

#### Interventions

Arthroplasty of the knee. There is only one treatment arm as the results of this arm will be compared to a historical control. The surgical procedure lasts 1.5 to 2 hours. Enrolment will take place over 9 months with 24 year follow-up there after, so any one patient will participate in the study for a maximum of 24 months.

#### Intervention Type

Procedure/Surgery

#### Primary outcome measure

The KSS Function score 6 months post-KineSpring<sup>™</sup> UKA System surgery

#### Secondary outcome measures

- 1. Procedural success (i.e., successful implantation of the device)
- 2. Treatment-emergent AEs at surgery, 2 and 6 weeks, 3, 6, 12, 18, and 24 months (to include device malfunctions/unanticipated adverse device evaluations (UADEs)

3. Subject reported symptom severity changes from baseline measurement at 6 weeks, 3, 6, 12,

- 18, and 24 months in the following criteria:
- 3.1. KOOS score
- 3.2. EuroQol (EQ-5D)
- 3.3. Lysholm Knee Scale
- 3.4. Knee Specific Pain Scale
- 3.5. Investigator's assessment of patients' global status
- 3.6. Activity Profile
- 3.7. Patient Overall Treatment Evaluation

4. KSS knee and function scores at 6 weeks, 3, 6, 12, 18, and 24 months

5. KineSpring™ UKA System stability through evaluation of radiographic parameters at 3, 6, 12, and 24 month follow-up

#### Overall study start date

30/09/2009

**Completion date** 

01/01/2014

## Eligibility

### Key inclusion criteria

1. Aged greater than or equal to 25 years, either sex

2. Diagnosis of medial OA of the target knee based on American College of Rheumatology (ACR) Clinical and Radiographic or Clinical Classification criteria for osteoarthritis with a minimum 12 month history

3. Continued knee pain despite minimum 3 months of conservative therapy, (i.e., physical therapy, bracing, orthotics, systemic or injected medications)

4. Knee flexion greater than or equal to 90 degrees

- 5. KSS knee and function scores less than 70
- 6. Weight greater than 60 kg
- 7. Ability to tolerate antibiotics

8. Willing and able to give voluntary written informed consent to participate in this clinical investigation

9. Prepared to consent to the transfer of his/her information to third parties

10. Willing to undertake the required investigational procedures and willing to return for the required follow-up evaluations

#### Participant type(s)

Patient

#### Age group

Adult

Sex

Both

Target number of participants

40

### Key exclusion criteria

1. Active infection, sepsis or osteomyelitis, history of infection in the target knee or distant foci of infections which may spread to the implant site

- 2. Rheumatoid arthritis or other forms of inflammatory joint disease
- 3. Significant OA in lateral or patellofemoral compartment
- 4. Previous surgery in the target knee within 12 months prior to screening
- 5. Previous osteotomy or failed knee endoprostheses of any kind in the target knee
- 6. Tibial-femoral varus or valgus alignment greater than 10 degrees
- 7. Ligamentous or meniscal instability as assessed by the Investigator
- 8. Concomitant immunosuppressive therapy
- 9. Paget's disease or metabolic disorders which may impair bone formation

10. Osteomalacia or moderate to severe osteoporosis, rapid joint destruction, marked bone loss or bone resorption noted on x-ray

11. Charcot's joint disease or other severe neurosensory deficits

12. Incomplete or deficient soft tissue surrounding the knee as assessed by the Investigator

13. Flexion deformity greater than 10 degrees

14. Uncontrolled diabetes mellitus or other significant co-morbidities

15. Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc) or other factor (e.g. planned relocation, uncooperative patient) that the Investigator feels would interfere with study participation

16. The patient is pregnant or lactating

17. Historic or ongoing litigation for or participation in workers compensation for musculoskeletal injuries or disorders

18. Subjects who are currently enrolled in another clinical investigation

## Date of first enrolment

30/09/2009

### Date of final enrolment

01/01/2014

## Locations

## Countries of recruitment

Belgium

England

United Kingdom

#### **Study participating centre Robert Jones and Agnes Hunt Orthopaedic and District Hospital** Oswestry United Kingdom SY10 7AG

## Sponsor information

**Organisation** Moximed Inc. (USA)

### Sponsor details

26460 Corporate Ave. Suite 100 Hayward, California United States of America 94545

**Sponsor type** Industry Website http://www.moximed.com/

ROR https://ror.org/04hrwvd56

## Funder(s)

Funder type Industry

Funder Name Moximed Inc. (USA)

## **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Not provided at time of registration